Biotech Values

[tinkershaw]

<<<I seem to remember reading that the FDA itself feels that there is a definite benefit to consumers if the FDA approves more than one ANDA…>>>

There is no benefit if a defective generic is let on the market and the market loses confidence in all generics because of the one bad egg let onto the market.

Also, if entry into generics becomes too easy, then fewer companies will pursue the generic jackpot.

So the above statement would appear not to be true except in certain contexts that may involve more competition equals better pricing. But that only applies if the generics all work as a bioequivalent of the existing product.

If MNTA is the only approved drug then you have a real blockbuster as it not only creates tons of cash flow but validates the technology and look for a large multiple. If all 3 drugs are approved then MNTA is just another generic drug maker and look for a lower multiple based on revenues.

My confidence is, if it was so easy to replicate Lovenox then why would any large pharma company need to share the profits with MNTA in order to accomplish this goal?

Whether or not TEVA and Amphastar have accomplished this feat without having to partner with MNTA we will have to see, but we know at least one big monied player felt they had to pay the price to MNTA in order to accomplish the goal of a true generic lovenox.

Tinker